证券日报网讯2月6日，安科生物（300009）在互动平台回答投资者提问时表示，公司生产经营一切正 常，不存在未及时披露的经营风险。目前公司在研产品的临床试验正在积极推进中，其中"HuA21注射 液"是公司自主研发的HER2靶点的一款新药，协同曲妥珠联用增加肿瘤抑制效果，前期探索性研究阶段 性数据呈现出较好的安全性和疗效，目前已顺利完成Ib/II期临床研究的受试者入组，将根据中期分析结 果计划开展III期临床研究，目前III期临床试验方案讨论会已经召开；"AK2024注射液"是公司开发的针 对HER2靶点的创新药物，目前正在开展I期临床试验，临床前研究表明，"AK2024注射液"可抑制HER2 阳性肿瘤细胞的增殖，在增强曲妥珠单抗对肿瘤生长的抑制作用方面，其协同效应明显优于帕妥珠单 抗；"HK010注射液"是公司开发的"PD-L1*4-1BB"双抗药物，目前完成II期临床试验的首例受试者入组 用药；"AK2017注射液"(重组人生长激素-Fc融合蛋白注射液)临床试验进展顺利，目前正在开展III期临 床试验；用于治疗呼吸道合胞病毒引起的儿童下呼吸道感染的"AK1012项目"(人干扰素α2b吸入用溶液) 已经完成I ...

Group 1: Company Strategy and Goals - The overall business goal for 2025 is to achieve restorative growth and maintain stable development [3] - The company aims to enhance the sales proportion of growth hormone water injections and expand the indications for growth hormone [3] - The company plans to accelerate the production capacity of the cancer drug Trastuzumab (Ansatin) and deepen brand building and market expansion [3] Group 2: Product Development and Clinical Trials - The clinical trial for "AK2017 Injection" (recombinant human growth hormone-Fc fusion protein injection) has successfully completed Phase II enrollment, with discussions for Phase III trial already held [3] - The company is actively promoting clinical trials for interferon spray and inhalation agents, targeting respiratory infections and gynecological diseases [3] - The "AK1008 Project" (human interferon α2b spray) is in Phase II trials for treating viral infections in children [3] Group 3: Competitive Landscape - Currently, there are 5 companies producing short-acting growth hormones, and several companies are expected to launch long-acting growth hormones [4] - The market for growth hormones is competitive but the overall pricing system remains stable [4] - The strategic partnership with Weisheng Pharmaceutical aims to cover the long-acting growth hormone market and enhance the company's competitiveness in children's growth and development [7] Group 4: Innovation and Collaborations - The company is developing several innovative drugs, including "HuA21 Injection" targeting HER2, which has shown promising safety and efficacy in early trials [4] - Collaboration with Afana Company on "AFN0328 Injection" for HPV precancerous lesions is in Phase I trials, with plans for further mRNA drug development [5] - The company is also involved in CAR-T cell therapy research through its investment in Boshengji Company, which has received implicit approval for clinical trials [5] Group 5: Market Expansion and Future Plans - The company is preparing to expand its international market presence by building FDA and EU-compliant production lines and engaging with foreign distributors [8] - The exclusive agency agreement with Baoji Pharmaceutical for the innovative drug "SJ02" aims to enhance the company's product matrix in the assisted reproduction field [8] - The company anticipates that the launch of long-acting growth hormones and long-acting follicle-stimulating hormones will provide new growth points for its business [8]